Free Trial

Neuphoria Therapeutics (NEUP) Competitors

Neuphoria Therapeutics logo
$8.40 +0.20 (+2.44%)
As of 04:00 PM Eastern

NEUP vs. ABVC, ADVM, NRXP, ATRA, VTVT, ANL, ANVS, QNTM, ALGS, and KRON

Should you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include ABVC BioPharma (ABVC), Adverum Biotechnologies (ADVM), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), vTv Therapeutics (VTVT), Adlai Nortye (ANL), Annovis Bio (ANVS), Quantum Biopharma (QNTM), Aligos Therapeutics (ALGS), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry.

Neuphoria Therapeutics vs. Its Competitors

ABVC BioPharma (NASDAQ:ABVC) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

ABVC BioPharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 17.1% of ABVC BioPharma shares are owned by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neuphoria Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. Neuphoria Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharma-963.46% -29.62% -14.08%
Neuphoria Therapeutics N/A N/A N/A

Neuphoria Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 150.00%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than ABVC BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Neuphoria Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

ABVC BioPharma has higher revenue and earnings than Neuphoria Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K108.21-$4.90M-$0.13-25.00
Neuphoria Therapeutics$10K1,579.20-$15.49MN/AN/A

In the previous week, ABVC BioPharma had 2 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for ABVC BioPharma and 1 mentions for Neuphoria Therapeutics. ABVC BioPharma's average media sentiment score of 0.99 beat Neuphoria Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
ABVC BioPharma Positive
Neuphoria Therapeutics Neutral

Summary

Neuphoria Therapeutics beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEUP vs. The Competition

MetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.42M$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E RatioN/A20.7327.9019.95
Price / Sales1,579.20321.12442.19102.72
Price / CashN/A43.2336.5558.97
Price / Book0.538.308.635.90
Net Income-$15.49M-$55.19M$3.24B$258.42M
7 Day Performance12.15%5.07%3.22%1.94%
1 Month Performance35.48%17.61%10.72%12.02%
1 Year PerformanceN/A7.03%34.94%20.81%

Neuphoria Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEUP
Neuphoria Therapeutics
1.3394 of 5 stars
$8.40
+2.4%
$21.00
+150.0%
N/A$15.42M$10K0.00N/APositive News
High Trading Volume
ABVC
ABVC BioPharma
0.7027 of 5 stars
$3.97
+18.5%
N/A+287.6%$56.89M$510K-30.5430High Trading Volume
ADVM
Adverum Biotechnologies
4.1222 of 5 stars
$2.54
-6.6%
$23.80
+837.0%
-65.6%$56.82M$1M-0.40190
NRXP
NRx Pharmaceuticals
2.3789 of 5 stars
$3.21
-1.8%
$28.50
+787.9%
+25.2%$56.54MN/A-1.602
ATRA
Atara Biotherapeutics
4.6441 of 5 stars
$9.23
-2.6%
$17.75
+92.3%
+17.5%$56.51M$128.94M-2.48330News Coverage
Positive News
Insider Trade
Gap Up
VTVT
vTv Therapeutics
1.5991 of 5 stars
$17.01
-2.8%
$35.50
+108.7%
-31.7%$55.90M$1.02M-5.659Positive News
ANL
Adlai Nortye
1.443 of 5 stars
$1.61
+6.6%
$9.00
+459.2%
-58.4%$55.72M$5M0.00127Gap Up
ANVS
Annovis Bio
2.2666 of 5 stars
$2.72
-4.6%
$18.00
+561.8%
-75.2%$55.54MN/A-1.263News Coverage
QNTM
Quantum Biopharma
N/A$18.68
-1.3%
N/AN/A$55.01MN/A-1.17N/A
ALGS
Aligos Therapeutics
3.7921 of 5 stars
$8.36
-4.9%
$70.00
+737.3%
-32.5%$53.74M$3.94M-0.4890News Coverage
Gap Down
KRON
Kronos Bio
N/A$0.88
+1.5%
$1.63
+84.7%
-35.8%$53.72M$9.85M-0.82100

Related Companies and Tools


This page (NASDAQ:NEUP) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners